Table 2.
Functional and demographic parameters of the study population according to upper limit of PDW values
| Parameter | PDW ≤16 (fL) n=69
|
PDW >16 (fL) n=10
|
Mean difference | Comparison result
|
|
|---|---|---|---|---|---|
| Mean | Mean | 95% CI | P-value | ||
| Age (years) | 73.57 | 74.1 | 0.64a | ||
| WBC (×10^3/µL) | 7.05 | 7.15 | 0.89a | ||
| Neutrophils (×10^3/µL) | 4.28 | 4.14 | 0.15 | −0.97, 1.26 | 0.8 |
| Lymphocytes (×10^3/µL) | 2.05 | 2.26 | 0.63a | ||
| Platelet count (×10^3/µL) | 229.94 | 183.5 | 46.44 | −17.74, 110.63 | 0.15 |
| MPV (fL) | 10.68 | 12.52 | −1.84 | −2.36, −1.32 | <0.001 |
| PLR | 125.34 | 107.89 | 0.42a | ||
| VC (L)b | 2.67 | 2.9 | −0.23 | −0.79, 0.32 | 0.4 |
| FVC (L)b | 2.65 | 2.89 | −0.24 | −0.8, 0.32 | 0.4 |
| FVC (%)b | 82.64 | 83.8 | −1.17 | −13.1, 10.76 | 0.85 |
| FEV1 (L)b | 1.59 | 1.82 | −0.23 | −0.65, 0.18 | 0.26 |
| FEV1 (%)b | 64.69 | 69.37 | −4.68 | −17.9, 8.54 | 0.48 |
| FEV1/FVCb | 0.6 | 0.57 | 0.2a | ||
| FEF 25–75 (L/s)b | 1.04 | 0.69 | 0.35 | 0.11, 0.59 | 0.007 |
| FEF 25–75 (%)b | 57.27 | 35.4 | 21.87 | 8.16, 35.58 | 0.003 |
| PEF (L/s)b | 4.13 | 3.17 | 0.96 | 0.32, 1.61 | 0.005 |
| PEF (%)b | 53.85 | 38.54 | 15.31 | 6.82, 23.78 | <0.001 |
| TLC (L) | 4.9 | 4.79 | 0.11 | −0.64, 0.88 | 0.76 |
| RV (L) | 2.39 | 2.65 | 0.25a | ||
|
| |||||
| Number of patients and percent n=69 | Number of patients and percent n=10 | P-value | |||
|
| |||||
| Gender | 0.51 | ||||
| Male | 44 (63.77%) | 8 (80%) | |||
| Female | 25 (36.23%) | 2 (20%) | |||
| Smoking history | 63 | 9 | 0.91 | ||
| Smoker | 15 (23.81%) | 3 (33.3%) | |||
| Non-smoker | 8 (12.7%) | 1 (11.1%) | |||
| Ex-smoker | 40 (63.49%) | 5 (55.6%) | |||
| GOLD stages of airway obstruction | 0.90 | ||||
| I | 16 (23.19%) | 4 (40%) | |||
| II | 35 (50.72%) | 4 (40%) | |||
| III | 15 (21.74%) | 2 (20%) | |||
| IV | 3 (4.35%) | 0 | |||
| Comorbidities | |||||
| Respiratory | 13 (18.84%) | 1 (10%) | 0.81 | ||
| Cardiovascular | 55 (79.71%) | 8 (80%) | 0.98 | ||
| Mental | 8 (11.59%) | 1 (10%) | 0.88 | ||
| Endocrine system | 9 (13.04%) | 2 (20%) | 0.92 | ||
| Central nervous system | 10 (14.49%) | 0 | 0.44 | ||
| Diabetes mellitus type 2 | 16 (23.19%) | 2 (20%) | 0.82 | ||
| Other | 40 (57.97%) | 7 (70%) | 0.7 | ||
Notes:
a
P-value for Mann–Whitney U test.
b
Post-bronchodilator values.
Abbreviations: FEF 25–75, forced expiratory flow between 25% and 75% of vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; MPV, mean platelet volume; PDW, platelet distribution width; PEF, peak expiratory flow; PLR, platelet-to-lymphocyte ratio; RV, residual volume; TLC, total lung capacity; VC, vital capacity; WBC, white blood count.